What does Syndax Pharmaceuticals, Inc. do?
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating…
What is Syndax Pharmaceuticals, Inc.'s P/E and P/B ratio?
Syndax Pharmaceuticals, Inc. has a P/E ratio of -5.4 and a P/B ratio of 80.25.
What is Syndax Pharmaceuticals, Inc.'s debt-to-equity ratio?
Syndax Pharmaceuticals, Inc. has a debt-to-equity ratio of 39.03.
How much does Syndax Pharmaceuticals, Inc. owe compared with what it owns?
Syndax Pharmaceuticals, Inc. owes $0.98 for every $1 it owns (balance sheet Jun 2026), which is high.
What is Syndax Pharmaceuticals, Inc.'s Positivity rank?
Syndax Pharmaceuticals, Inc. is ranked #6,709 of 6,775 companies globally and #3,939 of 4,000 in United States on PositoAI, with a Positivity Score of -57,751.
Does Syndax Pharmaceuticals, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Syndax Pharmaceuticals, Inc..
Where can I read the latest news about Syndax Pharmaceuticals, Inc.?
Recent headlines about Syndax Pharmaceuticals, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Syndax Pharmaceuticals, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Syndax Pharmaceuticals, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.